Originale
A variety of treatments have been tried in the management of PLGD (surgery, cyclosporine A, heparin, anti-inflammatories and steroids). These have offered very little benefit or clinical improvement. The administration of intravenous (IV) plasminogen (PLG) to bring PLG levels to normal or near normal levels appears to provide the most relief and greatest benefit.
PLASMINOGEN CONCENTRATES
Using fresh frozen plasma as a source of plasminogen, PLG concentrates given locally (specific to one area) and systemically (circulating throughout the body) have been shown to provide some symptom relief and may prevent lesions from reforming.
Locally administered fresh frozen plasma (which contains a low concentration of plasminogen) and other PLG-containing eye drops (generated from fresh frozen plasma) have shown some effectiveness in treating eye lesions associated with ligneous conjunctivitis. These drops require administration 3 to 4 times a day and are not widely commercially available. .
Purified Plasminogen Intravenous Therapy
Clinical trial results involving systemic treatment with purified IV plasminogen for patients with congenital plasminogen deficiency is currently under review by the FDA (2017). Results reported to date indicate that purified IV plasminogen therapy is effective at reducing and resolving both visible lesions, such as ligneous conjunctivitis and systemic lesions, such as those that arise in the respiratory tract ureter, uterus or on other mucosal surfaces. Patients in the trial had a 100% response rate and 90.9% of visible lesions were completely resolved after 12 weeks of therapy. Plasminogen therapy effectively prevented new lesions from forming during this 12-week interim analysis. Final results from the long-term, 48-week trial are not yet published. (C. Nakar, A. Shapiro et al., ISTH, 2017).